Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Un Nuovo Modo per Condividere i Piani di Radioterapia tra Medici, Studio CORRECT (CORRECT)

22 ottobre 2026 aggiornato da: Wake Forest University Health Sciences

Collaborazione Oncologica tra Radiologi e Radioterapisti Oncologi per la Valutazione dei Bersagli Contornati (CORRECT)

This clinical trial tests a new way to share radiation therapy plans using the Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) workflow to improve communication and collaboration between radiation oncologists (ROs) and radiologists when determining cancer targets for radiation treatment. Systemic barriers limit critical communication between radiation oncologists and radiologists and can lead to both under and overdosing of radiation therapy (RT) tumor targets and failures to properly interpret post-treatment imaging. The limited formal diagnostic radiology training of many providers can make differentiating normal from disease imaging findings during target determination difficult, especially in complex disease sites like the lung, head, and neck. Inaccurate target determination may result in cancer return, excess toxicity, or both. Likewise, radiologists who cannot access prior RT plans may mistake expected RT changes for recurrent cancer or overlook true progression. The CORRECT workflow was developed by ROs and radiologists to address RO-radiology communication barriers by facilitating sharing of comprehensive RT target contours during RT planning. The CORRECT workflow begins with the normal process of RO target contouring. Computed tomography (CT) images are then fused with RT targets and pushed to a pre-designated Picture Archiving and Communications System (PACS) software folder accessible by the radiology department. The radiologist can then review the fused images at their chosen time and annotate images to indicate potential deviations (e.g., not avoiding normal tissue or not including all tumor). The RO reviews the annotated images and decides if any changes to treatment targets are needed for the final treatment plan. Through this independent, asynchronous review of high-quality images, CORRECT overcomes many of the limitations of existing communication methods between RO-radiologist, fostering a more collaborative, efficient, and precise approach to cancer treatment planning.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVE:

To determine the feasibility of the CORRECT workflow, defined as the return of radiology feedback via CORRECT within 2 business days from receipt of initial RT targets.

SECONDARY OBJECTIVES:

I. To further assess the feasibility of the CORRECT workflow as measured by 1) time (in business days) required to install the information technology (IT) application at each practice, 2) the number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance, 3) percentage of approached patients who declined consent.

II. To assess ROs and radiologists' perceptions of acceptability, appropriateness and feasibility of the CORRECT workflow using the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM), along with the acceptability of CORRECT workflow training.

III. To identify facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial using a qualitative interview.

OUTLINE:

ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months

Tipo di studio

Interventistico

Iscrizione (Stimato)

194

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Karen Craver
  • Numero di telefono: 336-716-0891
  • Email: NCORP@wfusm.edu

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • PRACTICE: Must provide radiation therapy for ≥ 3 patients per month with lung cancer or head & neck cancer
  • PRACTICE: At least one radiation oncologist and one radiologist (in house, contracted, etc.) at the practice willing to participate, but may have multiple participants at the practice
  • PRACTICE: Radiation oncologist/radiologist team must use Picture Archiving and Communication System (PACS) software at this practice
  • RADIATION ONCOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIATION ONCOLOGIST (NON-PATIENT): Must treat lung and/or head & neck cancer patients with curative intent radiation therapy
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • RADIOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIOLOGIST (NON-PATIENT): Agree to review pre-treatment radiation therapy targets during the course of the study duration (approximately 12 months). Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • PATIENT: Must have any stage of clinically diagnosed lung or head & neck (HN) cancer
  • PATIENT: Planned treatment with curative intent definitive RT (with or without other treatments). Curative intent RT must be documented in the electronic medical record (EMR) by the treating radiation oncologist
  • PATIENT: Must be expected to be treated by a radiation oncologist participating in this study
  • PATIENT: Must be 18 years or older

Exclusion Criteria:

  • PRACTICE: Participation by the Community Site or Academic Community Site in another National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Cancer Care Delivery Research (CCDR) U34-supported protocol funded in NCI fiscal year 2025 or later. (Note: WF- 2301CD CONNECT is exempt from this policy, as it was funded prior to NCI fiscal year 2025.)
  • RADIATION ONCOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIATION ONCOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • RADIOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • PATIENT: Unable to understand English or Spanish
  • PATIENT: Early glottic larynx cancer planned for definitive RT alone

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Health Services Research (CORRECT workflow)

ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months.

Ancillary studies

Ancillary studies

Ancillary studies

Receive training and practice cases on CORRECT workflow

Use CORRECT workflow

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The return of radiology feedback via Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) (feasibility)
Lasso di tempo: Within 2 business days from receipt of initial radiation therapy (RT) targets

If > 50% of patients have target feedback returned to the radiation oncologist within 2 business days, this workflow will be considered feasible in community practice.

Within 2 business days from receipt of initial radiation therapy (RT) targets

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time (in business days) required to install the information technology (IT) application
Lasso di tempo: During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.

Will be assessed at each practice as tracked on the CORRECT IT data form

During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.
The number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance
Lasso di tempo: During RT planning for each patient; over the 9 months of of patient accrual

Will be assessed at each practice as tracked on the CORRECT IT data form.

During RT planning for each patient; over the 9 months of of patient accrual
Percentage of approached patients who declined consent
Lasso di tempo: During screening and enrollment over the 9 months of patient accrual

Will be assessed at each practice as tracked on the Patient Refusal form.

During screening and enrollment over the 9 months of patient accrual
Acceptability of the CORRECT workflow.
Lasso di tempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Acceptability of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Appropriateness of the CORRECT workflow
Lasso di tempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Intervention Appropriateness Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Feasibility of the CORRECT workflow
Lasso di tempo: Up to 2 months after patient enrollment has concluded

Will be assessed using the Feasibility of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score.

Up to 2 months after patient enrollment has concluded
Facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial
Lasso di tempo: Up to 2 months after patient enrollment has concluded

Will be identified using qualitative interviews using the radiation oncologist/radiologist interview guide.

Up to 2 months after patient enrollment has concluded

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Cattedra di studio: Kathryn Weaver, PhD, Wake Forest University Health Sciences

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 novembre 2028

Date di iscrizione allo studio

Primo inviato

4 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

12 dicembre 2025

Primo Inserito (Effettivo)

15 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IRB00141160
  • P30CA012197 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UG1CA189824 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U34CA297499 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI - 2025-07036 (Altro identificatore: NCI Trial Identifier)
  • WF-2402CD (Altro identificatore: CTEP Identifier)
  • WF-2402CD (Altro identificatore: Lead Organization Identifier)
  • WF-2402CD (Altro identificatore: DCP Identifier)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Periodo di condivisione IPD

6 months after publication for a 2 year duration

Criteri di accesso alla condivisione IPD

upon request to NCORP@wfusm.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .